<DOC>
	<DOCNO>NCT00005027</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness rebeccamycin analog treat patient advanced kidney cancer .</brief_summary>
	<brief_title>Rebeccamycin Analog Treating Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient advance renal cell carcinoma treat rebeccamycin analogue . - Assess quantitative qualitative toxicity associate drug patient population . OUTLINE : Patients receive rebeccamycin analogue IV 30-60 minute daily 5 day . Treatment continue every 21 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 23-44 patient accrue study within 9-18 month .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced unresectable , locally recurrent , metastatic renal cell carcinoma eligible high priority trial Measurable disease Longest diameter least 20 mm conventional technique least 10 mm spiral CT scan No nonmeasurable disease include : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No known brain metastasis History brain metastasis resect and/or irradiated subsequent normal brain CT scan allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : Greater 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ site No history allergic reaction attribute compound similar chemical biologic composition rebeccamycin analogue No concurrent uncontrolled illness ( e.g. , ongoing active infection ) No concurrent psychiatric illness social situation would preclude study compliance HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow Recovered toxic effect Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Other : No concurrent investigational commercial agent therapy renal cell cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>